Phospho-LATS1/2 (Ser909/Ser872) Antibody - #AF8163

(8)   (9)  
製品: Phospho-LATS1/2 (Ser909/Ser872) Antibody
カタログ: AF8163
タンパク質の説明: Rabbit polyclonal antibody to Phospho-LATS1/2 (Ser909/Ser872)
アプリケーション: WB IHC
反応性: Human, Mouse, Rat
予測: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Chicken, Xenopus
分子量: 126KD; 127kD,120kD(Calculated).
ユニプロット: O95835 | Q9NRM7
RRID: AB_2840225

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $350 在庫あり
 200ul $450 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MS Report
HPLC Report
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:1000-3000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Chicken(100%), Xenopus(100%)
クローナリティ:
Polyclonal
特異性:
Phospho-LATS1/2 (Ser909/Ser872) Antibody detects endogenous levels of LATS1/2 only when phosphorylated at Ser909/872.
RRID:
AB_2840225
引用形式: Affinity Biosciences Cat# AF8163, RRID:AB_2840225.
コンジュゲート:
Unconjugated.
精製:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

h-warts; Large tumor suppressor homolog 1; LATS large tumor suppressor homolog 1; LATS1; LATS1_HUMAN; Serine threonine protein kinase LATS1; Serine/threonine-protein kinase LATS1; WARTS; WARTS protein kinase; wts; FLJ13161; Kinase phosphorylated during mitosis protein; KPM; Large tumor suppressor homolog 2; Large tumor suppressor homolog 2 Drosophila; Large tumor suppressor kinase 2; LATS large tumor suppressor Drosophila homolog 2; LATS large tumor suppressor homolog 2; Lats2; LATS2_HUMAN; Serine/threonine kinase kpm; Serine/threonine protein kinase kpm; Serine/threonine-protein kinase kpm; Serine/threonine-protein kinase LATS2; Warts like kinase; Warts-like kinase;

免疫原

免疫原:
Uniprot:

O95835(LATS1_HUMAN) >>Visit HPA database.

Q9NRM7(LATS2_HUMAN) >>Visit HPA database.

遺伝子(ID):
LATS1(9113) | LATS2(26524)
発現特異性:
O95835 LATS1_HUMAN:

Expressed in all adult tissues examined except for lung and kidney.

Q9NRM7 LATS2_HUMAN:

Expressed at high levels in heart and skeletal muscle and at lower levels in all other tissues examined.

タンパク質配列:
MKRSEKPEGYRQMRPKTFPASNYTVSSRQMLQEIRESLRNLSKPSDAAKAEHNMSKMSTEDPRQVRNPPKFGTHHKALQEIRNSLLPFANETNSSRSTSEVNPQMLQDLQAAGFDEDMVIQALQKTNNRSIEAAIEFISKMSYQDPRREQMAAAAARPINASMKPGNVQQSVNRKQSWKGSKESLVPQRHGPPLGESVAYHSESPNSQTDVGRPLSGSGISAFVQAHPSNGQRVNPPPPPQVRSVTPPPPPRGQTPPPRGTTPPPPSWEPNSQTKRYSGNMEYVISRISPVPPGAWQEGYPPPPLNTSPMNPPNQGQRGISSVPVGRQPIIMQSSSKFNFPSGRPGMQNGTGQTDFMIHQNVVPAGTVNRQPPPPYPLTAANGQSPSALQTGGSAAPSSYTNGSIPQSMMVPNRNSHNMELYNISVPGLQTNWPQSSSAPAQSSPSSGHEIPTWQPNIPVRSNSFNNPLGNRASHSANSQPSATTVTAITPAPIQQPVKSMRVLKPELQTALAPTHPSWIPQPIQTVQPSPFPEGTASNVTVMPPVAEAPNYQGPPPPYPKHLLHQNPSVPPYESISKPSKEDQPSLPKEDESEKSYENVDSGDKEKKQITTSPITVRKNKKDEERRESRIQSYSPQAFKFFMEQHVENVLKSHQQRLHRKKQLENEMMRVGLSQDAQDQMRKMLCQKESNYIRLKRAKMDKSMFVKIKTLGIGAFGEVCLARKVDTKALYATKTLRKKDVLLRNQVAHVKAERDILAEADNEWVVRLYYSFQDKDNLYFVMDYIPGGDMMSLLIRMGIFPESLARFYIAELTCAVESVHKMGFIHRDIKPDNILIDRDGHIKLTDFGLCTGFRWTHDSKYYQSGDHPRQDSMDFSNEWGDPSSCRCGDRLKPLERRAARQHQRCLAHSLVGTPNYIAPEVLLRTGYTQLCDWWSVGVILFEMLVGQPPFLAQTPLETQMKVINWQTSLHIPPQAKLSPEASDLIIKLCRGPEDRLGKNGADEIKAHPFFKTIDFSSDLRQQSASYIPKITHPTDTSNFDPVDPDKLWSDDNEEENVNDTLNGWYKNGKHPEHAFYEFTFRRFFDDNGYPYNYPKPIEYEYINSQGSEQQSDEDDQNTGSEIKNRDLVYV

MRPKTFPATTYSGNSRQRLQEIREGLKQPSKSSVQGLPAGPNSDTSLDAKVLGSKDATRQQQQMRATPKFGPYQKALREIRYSLLPFANESGTSAAAEVNRQMLQELVNAGCDQEMAGRALKQTGSRSIEAALEYISKMGYLDPRNEQIVRVIKQTSPGKGLMPTPVTRRPSFEGTGDSFASYHQLSGTPYEGPSFGADGPTALEEMPRPYVDYLFPGVGPHGPGHQHQHPPKGYGASVEAAGAHFPLQGAHYGRPHLLVPGEPLGYGVQRSPSFQSKTPPETGGYASLPTKGQGGPPGAGLAFPPPAAGLYVPHPHHKQAGPAAHQLHVLGSRSQVFASDSPPQSLLTPSRNSLNVDLYELGSTSVQQWPAATLARRDSLQKPGLEAPPRAHVAFRPDCPVPSRTNSFNSHQPRPGPPGKAEPSLPAPNTVTAVTAAHILHPVKSVRVLRPEPQTAVGPSHPAWVPAPAPAPAPAPAPAAEGLDAKEEHALALGGAGAFPLDVEYGGPDRRCPPPPYPKHLLLRSKSEQYDLDSLCAGMEQSLRAGPNEPEGGDKSRKSAKGDKGGKDKKQIQTSPVPVRKNSRDEEKRESRIKSYSPYAFKFFMEQHVENVIKTYQQKVNRRLQLEQEMAKAGLCEAEQEQMRKILYQKESNYNRLKRAKMDKSMFVKIKTLGIGAFGEVCLACKVDTHALYAMKTLRKKDVLNRNQVAHVKAERDILAEADNEWVVKLYYSFQDKDSLYFVMDYIPGGDMMSLLIRMEVFPEHLARFYIAELTLAIESVHKMGFIHRDIKPDNILIDLDGHIKLTDFGLCTGFRWTHNSKYYQKGSHVRQDSMEPSDLWDDVSNCRCGDRLKTLEQRARKQHQRCLAHSLVGTPNYIAPEVLLRKGYTQLCDWWSVGVILFEMLVGQPPFLAPTPTETQLKVINWENTLHIPAQVKLSPEARDLITKLCCSADHRLGRNGADDLKAHPFFSAIDFSSDIRKQPAPYVPTISHPMDTSNFDPVDEESPWNDASEGSTKAWDTLTSPNNKHPEHAFYEFTFRRFFDDNGYPFRCPKPSGAEASQAESSDLESSDLVDQTEGCQPVYV

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Xenopus
100
Zebrafish
100
Chicken
100
Rabbit
100
Dog
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - O95835/Q9NRM7 基板として

Site PTM Type Enzyme
T17 Phosphorylation
Y23 Phosphorylation
S26 Phosphorylation
S27 Phosphorylation
S37 Phosphorylation
S42 Phosphorylation
K76 Ubiquitination
S84 Phosphorylation
Y143 Phosphorylation
S171 Phosphorylation
S177 Phosphorylation
S181 Phosphorylation
R243 Methylation
S244 Phosphorylation
T246 Phosphorylation
R252 Methylation
T255 Phosphorylation
R259 Methylation
T261 Phosphorylation
T262 Phosphorylation
K275 Methylation
Y277 Phosphorylation
S278 Phosphorylation
Y283 Phosphorylation
S336 Phosphorylation
S462 Phosphorylation
S464 Phosphorylation O60285 (NUAK1) , Q9H093 (NUAK2)
T490 Phosphorylation P06493 (CDK1)
S580 Phosphorylation
S596 Phosphorylation
T612 Phosphorylation
S613 Phosphorylation P06493 (CDK1)
T616 Phosphorylation
S633 Phosphorylation
S635 Phosphorylation
K662 Ubiquitination
S674 Phosphorylation O95835 (LATS1)
K688 Ubiquitination
K728 Ubiquitination
K734 Ubiquitination
K751 Sumoylation
S792 Phosphorylation
K830 Sumoylation
S864 Phosphorylation
S872 Phosphorylation Q13188 (STK3)
S909 Phosphorylation Q13043 (STK4) , Q13188 (STK3) , O95835 (LATS1)
T967 Phosphorylation Q13188 (STK3)
K976 Ubiquitination
S982 Phosphorylation
K1005 Ubiquitination
T1012 Phosphorylation Q13188 (STK3)
K1029 Ubiquitination
K1046 Ubiquitination
S1049 Phosphorylation O95835 (LATS1)
T1060 Phosphorylation Q13188 (STK3)
Y1076 Phosphorylation
T1079 Phosphorylation Q13043 (STK4) , Q13188 (STK3)
S1107 Phosphorylation
S1111 Phosphorylation
Site PTM Type Enzyme
T5 Phosphorylation
T9 Phosphorylation
T10 Phosphorylation
Y11 Phosphorylation
S12 Phosphorylation
S43 Phosphorylation
K50 Ubiquitination
K55 Acetylation
K55 Ubiquitination
Y82 Phosphorylation
S83 Phosphorylation O14965 (AURKA)
Y135 Phosphorylation
K154 Ubiquitination
S172 Phosphorylation O14757 (CHEK1) , O96017 (CHEK2)
S274 Phosphorylation
K278 Ubiquitination
T279 Phosphorylation
Y286 Phosphorylation
S288 Phosphorylation
S342 Phosphorylation
S380 Phosphorylation O14965 (AURKA) , O14757 (CHEK1) , O96017 (CHEK2)
S408 Phosphorylation O96017 (CHEK2) , O14757 (CHEK1)
S446 Phosphorylation O96017 (CHEK2) , O14757 (CHEK1)
S528 Phosphorylation
Y531 Phosphorylation
S535 Phosphorylation
S543 Phosphorylation
K565 Acetylation
K570 Acetylation
K571 Acetylation
T575 Phosphorylation
S576 Phosphorylation
S598 Phosphorylation
K620 Ubiquitination
K651 Ubiquitination
T690 Phosphorylation
K697 Ubiquitination
K793 Ubiquitination
K827 Ubiquitination
S829 Phosphorylation
S835 Phosphorylation Q9NRM7 (LATS2) , O14757 (CHEK1)
S872 Phosphorylation Q13043 (STK4) , Q13188 (STK3)
K939 Ubiquitination
K950 Ubiquitination
K968 Ubiquitination
K984 Ubiquitination
T1024 Phosphorylation
T1026 Phosphorylation
S1027 Phosphorylation
Y1038 Phosphorylation
T1041 Phosphorylation Q13188 (STK3) , Q13043 (STK4)
Y1051 Phosphorylation

PTMs - O95835/Q9NRM7 酵素として

Substrate Site Source
O14974 (PPP1R12A) S445 Uniprot
O95835 (LATS1) S674 Uniprot
O95835 (LATS1) S909 Uniprot
O95835 (LATS1) S1049 Uniprot
P04049 (RAF1) S259 Uniprot
P46937-2 (YAP1) S61 Uniprot
P46937-2 (YAP1) S109 Uniprot
P46937 (YAP1) S127 Uniprot
P46937-2 (YAP1) S164 Uniprot
P46937-2 (YAP1) S381 Uniprot
P46937 (YAP1) S397 Uniprot
Q02241 (KIF23) S716 Uniprot
Q02241 (KIF23) S814 Uniprot
Q8NHZ8 (CDC26) T7 Uniprot
Q9GZV5 (WWTR1) S89 Uniprot
Q9NQS7 (INCENP) S894 Uniprot
Substrate Site Source
O95863 (SNAI1) T203 Uniprot
P00519-2 (ABL1) T197 Uniprot
P38936 (CDKN1A) S146 Uniprot
P46937 (YAP1) S127 Uniprot
P46937 (YAP1) S397 Uniprot
P61981 (YWHAG) S59 Uniprot
Q02241 (KIF23) S716 Uniprot
Q02241 (KIF23) S814 Uniprot
Q4VCS5 (AMOT) S175 Uniprot
Q8NHZ8 (CDC26) T7 Uniprot
Q9GZV5 (WWTR1) S89 Uniprot
Q9NQS7 (INCENP) S894 Uniprot
Q9NRM7 (LATS2) S835 Uniprot
Q9Y2J4 (AMOTL2) S159 Uniprot

研究背景

機能:

Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function. Plays a role in mammary gland epithelial cells differentiation, both through the Hippo signaling pathway and the intracellular estrogen receptor signaling pathway by promoting the degradation of ESR1.

PTMs:

Autophosphorylated and phosphorylated during M-phase of the cell cycle. Phosphorylated by STK3/MST2 at Ser-909 and Thr-1079, which results in its activation. Phosphorylation at Ser-464 by NUAK1 and NUAK2 leads to decreased protein level and is required to regulate cellular senescence and cellular ploidy.

細胞の位置付け:

Cytoplasm>Cytoskeleton>Microtubule organizing center>Centrosome.
Note: Localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed in all adult tissues examined except for lung and kidney.

サブユニット構造:

Complexes with CDK1 in early mitosis. LATS1-associated CDK1 has no mitotic cyclin partner and no apparent kinase activity. Binds phosphorylated ZYX, locating this protein to the mitotic spindle and suggesting a role for actin regulatory proteins during mitosis. Binds to and colocalizes with LIMK1 at the actomyosin contractile ring during cytokinesis. Interacts (via PPxY motif 2) with YAP1 (via WW domains). Interacts with MOB1A and MOB1B. Interacts with LIMD1, WTIP and AJUBA. Interacts with ESR1, DCAF1 and DCAF13; probably recruits DCAF1 and DCAF13 to ESR1 to promote ESR1 ubiquitination and ubiquitin-mediated proteasomal degradation. Interacts with STK3/MST2; this interaction is inhibited in the presence of DLG5. Interacts with SCRIB in the presence of DLG5.

タンパク質ファミリー:

Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family.

機能:

Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor. Phosphorylates SNAI1 in the nucleus leading to its nuclear retention and stabilization, which enhances its epithelial-mesenchymal transition and tumor cell invasion/migration activities. This tumor-promoting activity is independent of its effects upon YAP1 or WWTR1/TAZ.

PTMs:

Autophosphorylated and phosphorylated during M-phase and the G1/S-phase of the cell cycle. Phosphorylated and activated by STK3/MST2.

細胞の位置付け:

Cytoplasm>Cytoskeleton>Microtubule organizing center>Centrosome. Cytoplasm. Cytoplasm>Cytoskeleton>Spindle pole. Nucleus.
Note: Colocalizes with AURKA at the centrosomes during interphase, early prophase and cytokinesis. Migrates to the spindle poles during mitosis, and to the midbody during cytokinesis. Translocates to the nucleus upon mitotic stress by nocodazole treatment.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed at high levels in heart and skeletal muscle and at lower levels in all other tissues examined.

サブユニット構造:

Interacts with and is phosphorylated by AURKA. Binds to AR. Interacts with AJUBA during mitosis and this complex regulates organization of the spindle apparatus through recruitment of gamma-tubulin to the centrosome. Interacts (via PPxY motif) with YAP1 (via WW domains). Interacts with MOB1A and MOB1B. Interacts with LIMD1, WTIP and AJUBA. Interacts with SNAI1.

タンパク質ファミリー:

Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family.

研究領域

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway - multiple species.   (View pathway)

参考文献

1). Melatonin reverses tumor necrosis factor-alpha-induced metabolic disturbance of human nucleus pulposus cells via MTNR1B/Gαi2/YAP signaling. International Journal of Biological Sciences, 2022 (PubMed: 35342351) [IF=9.2]

Application: WB    Species: human    Sample: NP cells

Figure 5. | YAP mediates melatonin-induced protective effects on NP cells in the presence of TNF-α.(E) WB assay of Hippo/YAP signaling proteins in NP cells following the indicated treatment.
2). USF1-induced upregulation of LINC01048 promotes cell proliferation and apoptosis in cutaneous squamous cell carcinoma by binding to TAF15 to transcriptionally activate YAP1. Cell Death & Disease, 2019 (PubMed: 30931936) [IF=9.0]

Application: WB    Species:    Sample: CSCC cells

Fig. 5| LINC01048 regulated the activity of Hippo pathway in CSCC cells. a 500 mRNAs were selected out due to their highest fold change in response to LINC01048 knockdown. b 500 mRNAs were subjected to KEGG pathway analysis. c The levels of Hippo pathway proteins were tested with western blotting in cells transfected with sh-LINC01048#2 or sh-NC
3). Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling. PHYTOMEDICINE, 2020 (PubMed: 32771890) [IF=7.9]

Application: WB    Species: human    Sample: LX-2 cells

Fig. 6.| PD inhibits liver fibrosis through regulation of Hippo pathway. (A) LX-2 cells were treated with PD (5 μM, 10 μM, 20 μM) for 24 h with or without TGF-β1(5 ng/ml). Western blot analysis of Hippo signaling core factor protein expression.
4). A derivant of ginsenoside CK and its inhibitory effect on hepatocellular carcinoma. LIFE SCIENCES, 2022 (PubMed: 35690105) [IF=6.1]
5). Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP. Cells, 2019 (PubMed: 30999669) [IF=6.0]
6). Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway. Molecular Therapy-Oncolytics, 2020 (PubMed: 32055676) [IF=5.7]

Application: WB    Species: human    Sample: FTC cells

Figure 4.| Upregulation of ST6GAL2 Rescues Tumorigenesis of FTC238 Cells and Resuppresses Hippo Signaling Pathway Activity(A–F) ST6GAL2 knockdown cells were transfected with ST6GAL2 overexpression vectors, and the proliferation,migration, and invasion capacities of FTC cells were enhanced. (G and H) Western blotting was performed to determine the levels of Hippo signaling molecules in FTC cells. *p < 0.05; scale bars, 20 mm.
7). Anti-cancer effects of nitazoxanide in epithelial ovarian cancer in-vitro and in-vivo. Chemico-biological interactions, 2024 (PubMed: 39084502) [IF=5.1]
8). Myricetin Suppresses the Propagation of Hepatocellular Carcinoma Cells by Down-Regulating Expression of YAP. , 2019

Application: WB    Species: Human    Sample: HepG2 cells

Fig. 4. myricetin promotes YAP phosphorylation and degradation via regulating LATS1/2 activity. (A-B) Cells were treated with myricetin for 1 h followed by western blot analysis of phosphorylation of indicated proteins. (C) HEK-293T cells were transfected with indicated plasmid for 72 hours, then treated with or without 200 μM for 1 hour followed by immunoprecipitation with His or Myc antibody respectively. The immunoprecipitated LATS1/2 proteins were incubated with immunoprecipitated YAP in kinase assay system, followed by western blot analysis. (D) HCC cells were transfected with LATS1/2 shRNA for 72 hours, then treated with or without 200 μM myricetin for 1 h followed by western blot analysis of phosphorylation of indicated proteins. (E) HCC cells were transfected with LATS1/2 shRNA for 24 hours, then treated with or without 200 μM myricetin for 48 hours followed by western blot analysis of expression of indicated proteins. (F) HepG2 cells were transfected with LATS1/2 shRNA for 48 hours, then were treated with 200 μM myricetin for 48 h followed by flow cytometry analysis apoptosis. Shown are representative flow cytometry plots (left). The apoptosis percentage was plotted (right). N = 3, ***, p < 0.001.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.